Pharma News

Aldevron, a subsidiary of Danaher, unveiled plans to expand its mRNA manufacturing operations to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities. ...

A labeling problem has forced Teva to recall 13 lots of fentanyl buccal tablets. Safety updates on the product insert were omitted, leaving the possibility of misuse that “could lead to life-thre...

The Food and Drug Administration (FDA) in the US has authorised the first approved drug for a rare form of motor neurone disease (MND) based on the results of a Phase 3 clinical trial completed at ...

Kite – a Gilead Sciences spin out company – has announced that the National Institute for Health and Care Excellence (NICE) has recommended additional uses for their two CAR T-cell therapies. ...

The CHMP’s positive opinion was supported by data obtained from a pivotal Phase II AReSVi-006 trial.

Eli Lilly and Co  on Thursday raised its annual revenue and profit forecasts after topping first-quarter sales estimates on demand for its closely watched diabetes drug Mounjaro, ahead of a d...

Sun Pharma says it's responding to increased pressure from the FDA following a plant inspection last August. 

The EU’s proposal for the biggest shake-up in pharma rules for decades has finally arrived, but companies say they could simply take their innovative medicines elsewhere. ...

Janssen Pharmaceuticals, a division of Johnson & Johnson, received European Commission marketing authorization for its prostate cancer drug Akeega (niraparib and abiraterone acetate), the first...

IN8bio Inc. on Tuesday said INB-400 and INB-410 received the U.S. Food and Drug Administration's orphan drug designation for a range of malignant glioma treatments, including newly diagnosed gliobl...

The results indicated TTHX1114 activated dose-dependent response in corneal oedema resolution and improved BCVA after surgery in all the patients.

AstraZeneca and Ionis Pharmaceuticals have reported that eplontersen met all co-primary endpoints and secondary endpoints in the Phase III NEURO-TTRansform trial in hereditary transthyretin-mediate...